|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.08.25 - 12:03
|
Gilead: Übernahme (Der Aktionaer)
|
|
|
Eine weitere Übernahme im Sektor: Die Biotech-Gesellschaft Gilead Sciences baut seine Entwicklungspipeline im Bereich der Onkologie weiter aus. Für einen dreistelligen Millionen-Dollar-Betrag wollen die Amerikaner den im Privatbesitz befindlichen Krebs-Spezialisten Interius BioTherapeutics schlucken....
|
|
|
|
|
|
|
21.08.25 - 15:01
|
Kite To Acquire Interius BioTherapeutics (AFX)
|
|
|
FOSTER CITY (dpa-AFX) - Kite, a Gilead Company (GILD), has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR th......
|
|
|
|
|
21.08.25 - 14:36
|
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform (Business Wire)
|
|
|
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million.
This acquisition complements Kite's expertise in cell therapy by incorporating Interius's integrating in vivo platform. This approach enables the generation of CAR T-cells directly within the patient's body and may offer a more durable and long-lasting therapeutic effect by inserting DNA into the patient's genome. Unlike traditional CAR T therapies that require cell harvesting, engineering and reinfusion, Interius's innovative, off-the-shelf yet personalized approach is designed to be delivered via a single intravenous infusion, eliminating the need for preconditioning chemotherapy and complex cell processing.
“In vivo therapy is a promising frontier with the potential to transform how we approach treating patients,...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
